Dr. Jaewoo Kang

Chief Executive Officer & Founder

• - Leading expert in AI-driven drug discovery.
• - Professor of Computer Science at Korea University (since 2006),
  previously at North Carolina State University.
• - Developed BioBERT, the most-cited biomedical AI language model (>7,000 citations).
• - Secured multiple AI drug discovery challenge wins and led collaborations with AstraZeneca
  on AI-driven frameworks.
• - B.S. in Computer Science from Korea University; M.S. from the University of Colorado Boulder; Ph.D. from the University of Wisconsin-Madison

Dr. Sunkyu Kim

Chief AI Officer

• - Expert in AI-driven drug discovery & computational biology.
• - Led AI initiatives in bioinformatics, pharmacogenomics, and cheminformatics.
• - Winner of BioCreative (2021), IDG-DREAM (2019), and NCI-CPTAC DREAM (2018).
• - Former Research Professor at Korea University.
• - B.S. & Ph.D in Computer Science and Engineering and M.S. in Bioinformatics from Korea University.

Dr. Kwang-Ok Lee

Senior Advisor

• - 30+ years in drug discovery & medicinal chemistry.
• - Former Chief Scientific Officer at AIGEN Sciences
• - Former leader at Hanmi Pharmaceutical, contributing to Poziotinib, Olmutinib, and BTK inhibitor HM71224.
• - Led R&D at Bukwang and Yungjin Pharmaceuticals.
• - Ph.D. in Medicinal Chemistry from Seoul National University.

Soojung Lee

Chief Operating Officer

• - Biotech executive with expertise in pharmacoeconomics, licensing, and business strategy.
• - Former Deputy BD Leader at Peptron.
• - Co-founder of G2GBIO, leading global licensing & clinical development.
• - Former BD & Clinical Development Lead at J2H Biotech.
• - B.S. in Microbiology & M.S. in Genetic Engineering from Seoul National University; Executive MBA from KAIST.

Dr. Hyunsun Park

EVP & Chief Business Officer

• - Global Business Development and Operations executive with a proven track record of driving strategic alliances, high-value out-licensing deals, and end-to-end drug development.
• - Former CBO/COO at AprilBio and PharmAbcine; CSO at BioLeaders; founder & CEO of Nasson Science; Director of Systems & Transitional Biology at CHDI Foundation and Management, Los Angeles, CA.
• - B.S. in Zoology from Seoul National University; Ph.D. in Molecular Pharmacology from Stanford University School of Medicine; Postdoctoral Fellow in Howard Huges Medical Institute, University of California, Los Angeles.

Dr. Sungbae Lee

EVP & Chief Scientific Officer

• - Medicinal chemist with 25+ years of experience in leading small-molecule drug discovery, structural optimization, and preclinical development across diabetes, oncology, immunology, and metabolic diseases.
• - Former Team Leader & Project Leader at LG Chem; Postdoctoral Researcher at KAIST.
• - B.S. in Chemistry from Kyung Hee University; M.S. in Chemistry from KAIST; Ph.D. in Chemistry from KAIST.

Dr. Eok Park

Chief Biology Officer

• - R&D executive with 20+ years of experience in translational biology, pharmacology/toxicology, and IND-enabling studies.
• - Former Lead of Pharmacology/Toxicology at LG Chem; co-founder of MitoImmune; EVP at ARBORMED; founder/CEO of N’WAVE.
• - B.S. & M.S. in Life Sciences from Sogang University; Ph.D. in Pharmacy from CHA University.

Sejeong Park

Director of AI Research

• - AI researcher with expertise combining machine learning and bioengineering, specializing in deep learning, cheminformatics, and AI-driven drug design.
• - Prior roles as Researcher at ExoCoBio.
• - B.S. in Biomedical Engineering from Korea University; M.S. in Bio and Brain Engineering from KAIST; Ph.D. Candidate in Computer Science from Korea University.

Mooyoung Seo

Director of Discovery Chemistry

• - Medicinal chemist with expertise in SAR/SPR-driven drug design, global CRO management, and preclinical candidate nomination in oncology, neurodegenerative, and inflammatory diseases.
• - Prior roles at Mitoimmune, Qurient, Institut Pasteur Korea (IPK), Korea Research Institute of Chemical Technology (KRICT), and Yuyu Pharma.
• - B.S. in Chemical Engineering and Nano-Bio Technology from Hannam University; M.S. in Chemical Engineering from Hannam University.

Miyeon Kim

Director of Discovery Chemistry

• - Medicinal chemist with expertise in advancing small molecules, TPDs, and ADCs from hit to preclinical candidate stages across oncology, autoimmune, and GI diseases.
• - Prior roles as Principal Scientist at Kanaph Therapeutics and Dong-A ST; Principal Scientist at Celltrion Pharm.
• - B.S. in Pharmacy from Pusan National University; M.S. in Pharmacy from Seoul National University; Ph.D. candidate of Industrial Pharmacy at Gachon University.

Jongseung Kim

• - Professor, Department of Chemistry, Korea University (2007–present)
• - Director, Creative Research Initiative Project (2009–present)
• - Member, Korea Academy of Science and Technology (2014–present)
• - Ph.D. in Organic Chemistry, Texas Tech University, USA
• - Research Interests: Cancer (CRC, TNBC), Neurodegeneration

Kyonghwa Park

• - Professor, Oncology and Hematology, Anam Hospital, Korea University (2007–present)
• - Member, Korean Association of Internal Medicine, Korean Cancer Association, AACR
• - Ph.D., College of Medicine, Korea University (2005)
• - M.D., College of Medicine, Korea University (1998)
• - Research Interests: Cancer (Breast, Gynecologic, Urologic)

Sangjoon Shin

• - Professor, Department of Internal Medicine, College of Medicine, Yonsei University (2013–present)
• - Member, Korean Cancer Association, Korean Society of Medical Oncology, ASCO, AACR, ESMO
• - Ph.D., College of Medicine, Yonsei University (2011)
• - M.D., College of Medicine, Yeungnam University (1998)
• - Research Interests: Cancer (Colorectal, Melanoma, Urologic)